Today: 11 June 2026
Browse Category

Pharmaceutical Industry 29 November 2025 - 11 December 2025

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences shares surged over 180% in a week after Phase 1 data showed its obesity drug WVE-007 reduced visceral fat by up to 10% and increased lean mass. The stock hit a five-year high near $22 before retreating to $17.06 following a $350 million equity offering and insider selling. Analyst price targets jumped, but Wave remains unprofitable with high valuation risk.
11 December 2025
···
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics shares traded near $46 on December 11, 2025, after announcing a $261 million stock offering at $42.50 per share. The company filed a Biologics License Application for atacicept in IgA nephropathy and reported strong late-stage clinical results. Shares are up nearly 100% in six months, with market cap around $2.9–3.0 billion. The offering is expected to close today.
11 December 2025
·
Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals shares surged to a new 52-week high above $72 on December 11 after the FDA approved its first drug, Redemplo, for familial chylomicronemia syndrome. The stock has climbed from the low-$40s to around $70 in a month, pushing market value to $9.6 billion, up over 300% year-over-year. The company also received an FDA Breakthrough Therapy designation and launched its first Alzheimer’s trial.
11 December 2025
··
Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer shares closed down 1.7% at $25.33 on December 9, 2025, with volume below average. After hours, the stock edged up to $25.40 as investors reacted to Pfizer’s new global licensing deal with YaoPharma for an early-stage oral obesity drug. The agreement includes a $150 million upfront payment and potential milestones up to $2.1 billion.
10 December 2025
····
Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

Eli Lilly shares traded near $980 Tuesday, down 1.6% but up 57% from their 52-week low, with a market cap around $880 billion after briefly topping $1 trillion in November. The company announced a $6 billion manufacturing facility in Alabama, reported strong Q3 earnings, raised guidance, and posted an 80% risk reduction in a key leukemia trial. Lilly also closed its Adverum acquisition and raised its dividend.
9 December 2025
·
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Kymera Therapeutics shares jumped 41.6% to close at $94.30 on December 8 after its oral STAT6 degrader KT-621 showed dupilumab-like efficacy and clean safety in a small Phase 1b eczema trial. The company announced a $500 million stock offering the same day, sending shares lower in after-hours trading. Analyst price targets rose, some reaching $138.
9 December 2025
····
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics shares doubled to $69.98 mid-day December 9 after reporting strong Phase 2b data for its oral obesity drug, aleniglipron. The 120 mg dose showed 11.3% placebo-adjusted weight loss over 36 weeks; higher doses reached 15.3%. No drug-induced liver injury or QTc prolongation was reported. Market cap stands near $4 billion, with the stock trading close to its 52-week high.
9 December 2025
··
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences shares surged 147% to $18.52 after reporting positive Phase 1 data for its RNA obesity drug WVE-007 on December 8, raising its market cap to $3 billion. The company launched a $250 million equity offering following the rally. Interim results showed a 9.4% reduction in visceral fat and a 3.2% gain in lean mass after one dose, outperforming GLP-1 drugs in early comparisons.
9 December 2025
···
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics shares jumped nearly 50% Monday, closing near $96 after hitting an intraday high above $100, following strong Phase 1b results for its oral STAT6 degrader KT‑621 in atopic dermatitis. The trial showed about 98% median STAT6 degradation in blood and 94% in skin lesions. Trading volume was far above normal. Stifel raised its price target as the stock marked a new 52-week high.
8 December 2025
··
Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics shares surged 101% to $69.46 on December 8 after reporting positive Phase 2b data for aleniglipron, its oral GLP-1 agonist for obesity. Patients on 120 mg lost 12.1% of body weight at 36 weeks versus 0.8% for placebo. The company held $799 million in cash as of September 30.
8 December 2025
···
Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer shares closed at $26.03 on December 5, 2025, up 1.28% and 24% above April’s low. The stock yields about 6.6% with an annualized dividend of $1.72 per share and has paid 347 consecutive quarterly dividends. Pfizer’s Q3 revenue fell 6% to $16.65 billion, but adjusted EPS beat expectations at $0.87. The stock trades at 8–9x forward earnings, below the market average.
6 December 2025
···
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines shares jumped nearly 40% intraday on December 5 after its pivotal epilepsy trial was stopped early for efficacy and the company reported a positive pre-NDA meeting with the FDA for its essential tremor drug. By late morning, PRAX traded around $265–266, hitting a new 52-week high and pushing its market cap above $1.1 billion. The stock is up over 200% year-to-date.
5 December 2025
·
Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

Merck shares closed at $100.86 on December 4, down 1.4%, with after-hours trading flat. Scotiabank raised its price target to $120, echoing similar moves by Goldman Sachs and Wells Fargo. Keytruda sales rose 10% in Q3 to $8.1 billion, but Gardasil fell 24% amid weaker China demand. The stock’s market cap stands near $250 billion.
4 December 2025
··
Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon Ltd. shares surged to $13–15 by early afternoon December 4, more than doubling from the previous close of $7.09, after hitting intraday highs above $18. The rally followed news of a manufacturing milestone for its PL‑14 allergy nasal spray and new preclinical data showing improved mucoadhesion for its naloxone hydrogel. Polyrizon, based in Israel, has no approved products and reported a 2024 net loss of about $1.5 million.
4 December 2025
··
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics shares surged over 500% on December 3, 2025, after its Phase 3 HOPE‑3 trial of Deramiocel in Duchenne muscular dystrophy met all primary and key secondary endpoints. The trial showed a 54% slowing of upper limb decline and 91% preservation of heart function versus placebo. Capricor plans to resubmit its BLA to the FDA, addressing a previous Complete Response Letter. The stock traded around $39–40 intraday, up from $6.36.
3 December 2025
···
Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

A U.S. federal judge allowed a $6.7 billion lawsuit against Bristol-Myers Squibb over its 2019 Celgene acquisition to proceed, rejecting the company’s motion to dismiss key claims. BMY shares closed at $49.18 on December 1, up 7–8% over five days, but remain down for the year. The company’s annual dividend yield is about 5%. New cell therapy approvals and strong ASH 2025 hematology data also drew investor attention.
2 December 2025
·
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer shares closed at $25.74 on November 28, 2025, down 1.8% over the past year. Regulatory filings show new institutional buying, and the company completed a Metsera acquisition worth up to $10 billion. Pfizer reduced its BioNTech stake by 54.7% and raised its full-year EPS guidance to $3.00–$3.15 after reporting $16.7 billion in Q3 revenue.
30 November 2025
····
Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck shares closed at $104.83 on November 28, just below the 52-week high of $105.84 set earlier in the week after a Wells Fargo upgrade. The stock is up about 21% over the past month and 8% year-to-date. Scotia Capital and Level Four Advisory Services have trimmed their Merck holdings, according to new filings. Merck continues to warn investors about an unsolicited mini-tender offer from Tutanota LLC at $65 per share.
29 November 2025
·
1 … 5 6 7 8 9

Stock Market Today

  • Telesat (TSAT) Valuation Assessed After Significant Share Price Increase
    June 10, 2026, 7:32 PM EDT. Telesat (TSAT) shares surged 405% over three years but dropped 20% last month, trading at $43.89. The company reports CA$388.3 million revenue with a CA$185.3 million loss. Telesat's Price-to-Sales (P/S) ratio stands at 2.4x, above the US Telecom average of 1.3x and peer average of 2.3x, indicating relatively high investor expectations. However, a regression-based fair P/S of 8.8x suggests the market may undervalue future growth if assumptions hold. Risks include dependence on Geostationary Earth Orbit (GEO) revenue and potential setbacks in Low Earth Orbit (LEO) projects. Investors are advised to weigh the significant potential upside against these operational challenges and market sentiment.

Latest articles

Lloyds stock drifts lower as FCA car finance hold clouds buyback hopes

Lloyds stock drifts lower as FCA car finance hold clouds buyback hopes

11 June 2026
Lloyds shares fell 0.98% as the FCA told Parliament that motor-finance compensation payments are now unlikely before 2027 due to legal challenges, prolonging uncertainty over redress costs and capital returns; investors must wait for clarity, with the next key update due July 30.
Nokia Slides, Nvidia AI-RAN Trade Cools Ahead of Key Test

Nokia Slides, Nvidia AI-RAN Trade Cools Ahead of Key Test

11 June 2026
Nokia’s U.S. ADR plunged 3.25% to $13.40, extending losses after a 5.07% drop, as investors reacted to risks from Nvidia’s push into mobile-network tech, raising doubts about Nokia’s role in AI infrastructure and overshadowing new 5G and AI product launches; shares now sit 23% below last week’s high.
Go toTop